Shilpa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHILPA, and when can generic versions of SHILPA drugs launch?
SHILPA has thirteen approved drugs.
There are five US patents protecting SHILPA drugs. There are two tentative approvals on SHILPA drugs.
There are fifty-four patent family members on SHILPA drugs in twenty-six countries and forty-eight supplementary protection certificates in sixteen countries.
Summary for Shilpa
| International Patents: | 54 |
| US Patents: | 5 |
| Tradenames: | 11 |
| Ingredients: | 11 |
| NDAs: | 13 |
| Patent Litigation for Shilpa: | See patent lawsuits for Shilpa |
Drugs and US Patents for Shilpa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 210327-003 | May 16, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Shilpa | GEMCITABINE HYDROCHLORIDE | gemcitabine hydrochloride | INJECTABLE;INJECTION | 207575-001 | Feb 22, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 10,842,770 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-003 | Dec 22, 2015 | AP | RX | Yes | Yes | 8,940,786 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-002 | Dec 22, 2015 | AP | RX | Yes | Yes | 8,940,786 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Shilpa | GEMCITABINE HYDROCHLORIDE | gemcitabine hydrochloride | INJECTABLE;INJECTION | 210991-001 | Oct 4, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shilpa Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2798180 | ⤷ Sign Up |
| Singapore | 185389 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2014055426 | ⤷ Sign Up |
| Canada | 2885930 | ⤷ Sign Up |
| European Patent Office | 2566474 | ⤷ Sign Up |
| Colombia | 6640232 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shilpa Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0122707 | 96C0030 | Belgium | ⤷ Sign Up | PRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327 |
| 1746976 | 300885 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IRINOTECANSUCROSOFAATZOUT; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
| 2962690 | 2019/037 | Ireland | ⤷ Sign Up | PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/981 20150115 |
| 0316704 | 2001C/021 | Belgium | ⤷ Sign Up | PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610 |
| 0275821 | 01C0035 | France | ⤷ Sign Up | PRODUCT NAME: ZOLEDRONIC ACID; NAT REG. NO/DATE: EU/1/01/176/001 20010320; FIRST REG.: LI IKS N 55 463 20001128 |
| 0316704 | C300045 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
